Meeting
2020 ASCO Virtual Scientific Program
Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.
Authors
Ralph Zinner
University of Kentucky, Department of Medical Oncology, Lexington, KY
Ralph Zinner , Rita Axelrod , Charalambos C Solomides , Scott Cowan , Benjamin Leiby , Avnish K Bhatia , Mark L. Sundermeyer , D. Craig Hooper , Larry Harshyne , Grace L. Lu-Yao , Belen C Quereda-Bernabeu , Sung C Whang , Suzanne C OHara , Daniel C Vernau , Maria Werner-Wasik , Bo Lu , Jennifer M Johnson , Walter C Scott , Athanassios Argiris , Nathaniel R. Evans
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03366766
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9051)
DOI
10.1200/JCO.2020.38.15_suppl.9051
Abstract #
9051
Poster Bd #
244
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2014 ASCO Annual Meeting
A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).
First Author: David Paul Carbone
Poster
2023 ASCO Annual Meeting
ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC).
First Author: Hailiang Zhang
Poster
2022 ASCO Annual Meeting
Neoadjuvant nivolumab in early-stage non–small cell lung cancer (NSCLC): Five-year outcomes.
First Author: Samuel Rosner